Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04421027 · OUTCOME

Number of Days of Resting Respiratory Rate <24 Breaths Per Minute

A Study of Baricitinib (LY3009104) in Participants With COVID-19 · Source last updated 2022-07-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
LEAST_SQUARES_MEAN
Unit
days
Interval / dispersion
Standard Error
Time frame
Day 1 to Day 28

What was measured

Number of days of resting respiratory rate \<24 breaths per minute.

Analysis population: All participants randomly assigned to study intervention who had non-missing baseline and at least 1 postbaseline respiratory rate.

Groups in this outcome

Placebo + SOC

Placebo administered orally QD with standard of care.

Baricitinib + SOC

4 mg baricitinib administered orally QD with standard of care.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo + SOC743
Baricitinib + SOC745

Reported measurements

Source class 1
Values in days · Interval/dispersion: Standard Error
GroupValueSpreadLowerUpperComment
Placebo + SOC9.620.300Not reportedNot reportedNot reported
Baricitinib + SOC9.730.304Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    -0.49
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.72
    dispersion Type
    STANDARD_ERROR_OF_MEAN
    dispersion Value
    0.306
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.7073
    param Type
    LS Mean Difference (Net)
    param Value
    0.11
    statistical Method
    ANOVA
Complete source fields
analyses
  1. ci Lower Limit
    -0.49
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.72
    dispersion Type
    STANDARD_ERROR_OF_MEAN
    dispersion Value
    0.306
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.7073
    param Type
    LS Mean Difference (Net)
    param Value
    0.11
    statistical Method
    ANOVA
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        0.300
        value
        9.62
      2. group Id
        OG001
        spread
        0.304
        value
        9.73
denoms
  1. counts
    1. group Id
      OG000
      value
      743
    2. group Id
      OG001
      value
      745
    units
    Participants
description
Number of days of resting respiratory rate \<24 breaths per minute.
dispersion Type
Standard Error
groups
  1. description
    Placebo administered orally QD with standard of care.
    id
    OG000
    title
    Placebo + SOC
  2. description
    4 mg baricitinib administered orally QD with standard of care.
    id
    OG001
    title
    Baricitinib + SOC
param Type
LEAST_SQUARES_MEAN
population Description
All participants randomly assigned to study intervention who had non-missing baseline and at least 1 postbaseline respiratory rate.
reporting Status
POSTED
time Frame
Day 1 to Day 28
title
Number of Days of Resting Respiratory Rate <24 Breaths Per Minute
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice